Gena Wang
Stock Analyst at Barclays
(2.23)
# 2,663
Out of 4,876 analysts
202
Total ratings
39.85%
Success rate
-3.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $89 → $29 | $17.25 | +68.12% | 10 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $57 → $59 | $30.04 | +96.40% | 3 | Jun 10, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $10 | $4.78 | +109.21% | 7 | May 16, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $9 → $5 | $0.55 | +804.98% | 4 | May 14, 2025 | |
| CLLS Cellectis | Maintains: Overweight | $5 → $4 | $1.50 | +166.67% | 4 | May 13, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $56 → $42 | $46.66 | -9.99% | 16 | May 9, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $45 → $38 | $4.01 | +847.70% | 2 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $56 → $42 | $49.49 | -15.13% | 15 | May 8, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $55 → $53 | $33.71 | +57.22% | 2 | May 8, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Equal-Weight | $8 → $11 | $9.57 | +14.94% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $31 → $25 | $17.11 | +46.11% | 9 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $40 | $27.28 | +46.63% | 9 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.18 | +498.46% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $9.75 | +166.67% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $443.88 | +5.21% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.27 | +32.16% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3 → $4 | $3.77 | +6.10% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $319.00 | +3.13% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $54.75 | +57.08% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $8.94 | +459.28% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $36.45 | +122.22% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $51 | $39.96 | +27.63% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $35.00 | +168.61% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $12.29 | -26.77% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $13.80 | +81.16% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $6.71 | +168.46% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $3.34 | +169.87% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.81 | +4,637.30% | 1 | Jan 6, 2017 |
Sarepta Therapeutics
Jun 17, 2025
Maintains: Overweight
Price Target: $89 → $29
Current: $17.25
Upside: +68.12%
Avidity Biosciences
Jun 10, 2025
Maintains: Overweight
Price Target: $57 → $59
Current: $30.04
Upside: +96.40%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $4.78
Upside: +109.21%
Sangamo Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.55
Upside: +804.98%
Cellectis
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $1.50
Upside: +166.67%
CRISPR Therapeutics AG
May 9, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $46.66
Upside: -9.99%
4D Molecular Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $4.01
Upside: +847.70%
PTC Therapeutics
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $49.49
Upside: -15.13%
Cytokinetics
May 8, 2025
Maintains: Overweight
Price Target: $55 → $53
Current: $33.71
Upside: +57.22%
BioCryst Pharmaceuticals
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $9.57
Upside: +14.94%
May 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $17.11
Upside: +46.11%
May 2, 2025
Maintains: Equal-Weight
Price Target: $45 → $40
Current: $27.28
Upside: +46.63%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.18
Upside: +498.46%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $9.75
Upside: +166.67%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $443.88
Upside: +5.21%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.27
Upside: +32.16%
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $3.77
Upside: +6.10%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $319.00
Upside: +3.13%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $54.75
Upside: +57.08%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $8.94
Upside: +459.28%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $36.45
Upside: +122.22%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $45 → $51
Current: $39.96
Upside: +27.63%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $35.00
Upside: +168.61%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $12.29
Upside: -26.77%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $13.80
Upside: +81.16%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $6.71
Upside: +168.46%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $3.34
Upside: +169.87%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.81
Upside: +4,637.30%